Director of Quality Assurance Job Description

A Director of Quality Assurance makes sure the organization's regulated work, whether that is clinical trials, manufacturing, or laboratory testing, is conducted in line with FDA, EMA, and ICH requirements. When a health authority inspector arrives, the QA Director is the person who prepared for that visit and carries the most direct accountability for how it goes.

The quality management system (QMS) is the framework the Director builds and keeps current: SOPs that define how every regulated task is performed, a CAPA system that captures and resolves quality problems, deviation management that documents and investigates departures from procedure, and training records proving everyone doing regulated work is qualified to do it. As of February 2, 2026, device-focused QA Directors also have to keep that framework aligned with FDA's Quality Management System Regulation (QMSR), which replaced the older 21 CFR Part 820 by folding in ISO 13485:2016. The substance of the requirements did not change much, but the structure, terminology, and cross-references in every SOP that cited Part 820 now need to point to the harmonized standard instead.

Audit execution is the most active ongoing function. Internal audits check whether the organization's own procedures are actually being followed. Vendor audits check whether CROs, testing labs, and clinical suppliers meet the organization's standards and applicable regulations. Findings go into reports, reports require corrective actions, and corrective actions require follow-up to confirm they worked. A quality function that audits but never verifies its own CAPAs is producing paperwork, not assurance.

Inspection preparedness is where the role earns its salary. An FDA inspection is not pass or fail, it runs on a continuum from no findings to a warning letter to a consent decree, and the gap between a clean inspection and a Form 483 with multiple observations usually traces back to how ready the organization was before the inspector walked in. Mock inspections, document dry runs, back-room team drills, and rehearsed response protocols produce measurably better outcomes, and the Director is the one who runs those drills months ahead of an expected inspection window.

On the clinical side, the Director also has to track the rollout of ICH E6(R3), the current Good Clinical Practice guideline. Its core principles and first annex have been in effect in the EU since July 2025, and the technology-and-data-focused Annex 2 was adopted in June 2026 for a January 2027 effective date, which means GCP audit checklists and vendor oversight plans are mid-transition for organizations running international trials right now.

Education:

• Bachelor's degree in pharmacy, chemistry, biology, or engineering required, since the role has to evaluate scientific and manufacturing data, not just process paperwork
• Master's degree in quality, regulatory affairs, or a life science preferred at the director level, especially at large pharma and device companies
• RAC (Regulatory Affairs Certification) from RAPS is highly valued and signals fluency across the full regulatory lifecycle
• CQA (Certified Quality Auditor) from ASQ or an equivalent industry credential demonstrates formal audit training rather than on-the-job learning alone

Experience:

• 15 to 20 years in pharmaceutical, biotech, or medical device quality roles, typically climbing from QA associate through QA manager before reaching director
• Direct experience leading at least one FDA CGMP or BIMO inspection, in either the front room or the back room, is close to a hard requirement at this level
• CAPA system ownership and audit program management at the department level, including responsibility for on-time closure rates
• Vendor audit experience conducting audits of CROs, CDMOs, or testing laboratories, since most organizations rely on outside vendors for part of their regulated work
• Warning letter response or consent decree remediation experience is a strong differentiator, because it shows the candidate can manage a crisis, not just steady-state operations

Regulatory knowledge:

• GMP: 21 CFR Parts 210 and 211 for drugs, the QMSR (effective February 2, 2026, incorporating ISO 13485:2016) for devices, and ICH Q7 and Q10 for active ingredients and pharmaceutical quality systems
• GCP: 21 CFR Part 312 and ICH E6(R3), including the Annex 2 provisions adopted in June 2026 that address clinical data and technology oversight
• GLP: 21 CFR Part 58 for non-clinical laboratory quality
• FDA 21 CFR Part 11 and EU Annex 11 for computer systems validation, covering audit trails and access controls on any system used in regulated work
• ICH Q9 for quality risk management, alongside the January 2026 EMA/FDA joint guiding principles for AI use in evidence generation and manufacturing

Systems and process knowledge:

• Electronic quality management systems such as Veeva Vault QMS, TrackWise, or MasterControl, and the ability to configure workflows rather than just use them
• Computer system validation under the GAMP 5 framework, including UAT documentation and IQ/OQ/PQ protocols for manufacturing and lab equipment
• Change control processes, including impact assessment and regulatory notification requirements when a change affects a licensed product
• SOP architecture, including version control, periodic review cycles, and approval workflows that hold up under inspection scrutiny

Directors of Quality Assurance are essential in regulated industries, and demand for experienced QA leadership stays consistently strong. Every pharmaceutical, biotech, and medical device company operating in FDA-regulated markets needs a functioning quality system. It is not optional, and the penalty for a broken one is severe: warning letters, consent decrees, plant shutdowns, and product recalls.

Growth in the life sciences sector has widened total demand for QA leadership. More products, more manufacturing sites, and more clinical programs all mean more quality oversight. Investment in new biologics and cell and gene therapy manufacturing in particular has created openings for QA Directors who can build a quality system from the ground up rather than maintain an existing one.

Two 2026 regulatory shifts are reshaping the job description in real time. The FDA's Quality Management System Regulation became effective February 2, 2026, and companies with device operations are still updating SOPs, training records, and internal audit checklists to reference ISO 13485:2016 instead of the legacy 21 CFR Part 820 language. Separately, the FDA and EMA jointly published ten guiding principles for AI use across the medicine lifecycle in January 2026, giving QA Directors their first cross-agency reference point for evaluating AI-assisted deviation detection, CAPA root-cause tools, and document management systems rather than assessing them ad hoc.

The talent market at director level stays tight. QA leadership is a specialized track, and not every quality professional accumulates the inspection management experience and regulatory breadth the title requires. Companies approaching their first CGMP inspection or commercial manufacturing launch recruit aggressively for QA Directors with that specific track record, and are often willing to pay a premium for someone who has already carried a company through a Form 483 without escalation to a warning letter.

Salary data for the title varies widely by source and industry mix: general "director of quality" postings average in the low $200,000s nationally as of mid-2026, while pharma- and device-specific roles that carry inspection accountability and GMP liability tend to sit at or above that range. CRO-side and purely GCP-focused Director roles typically land lower than sponsor-side manufacturing quality roles, reflecting the difference in regulatory exposure between the two paths. The path from Director to VP of Quality or Chief Quality Officer is well established for those with multiple successful inspections and quality system builds behind them, and that next step typically comes with a substantial compensation increase along with broader responsibility across sites or product lines rather than a single facility or program.

Dear Hiring Manager,

I'm writing to apply for the Director of Quality Assurance position at [Company]. I currently serve as Senior QA Manager at [Company], where I have led the GCP and GMP quality programs for a mid-size clinical-stage biotech for the past five years. I've managed two FDA BIMO inspections and one EMA GMP inspection of our contract manufacturer during that time, and all three closed without warning letters.

The work I'm most proud of is the CAPA system rebuild I led after joining [Company]. The existing system had 47 open CAPAs, 22 of them past due, with no consistent check on whether closed CAPAs had actually resolved the original problem. I redesigned the CAPA workflow in our eQMS, added a monthly effectiveness check, and drove the backlog to zero in eight months. The following FDA inspection specifically noted our CAPA system as a strength.

I hold a RAC credential and a master's in pharmaceutical sciences, and I have direct experience drafting Form 483 responses and coordinating the corrective action commitments that follow. I've also led 14 audits of CROs and testing labs across three programs, with findings that directly shaped our approved supplier list. I've begun updating our device-side SOPs to the QMSR/ISO 13485 structure ahead of the February 2026 effective date, so I would bring that transition experience on day one.

I'm looking for a director-level role at a company approaching commercial stage, where I can build the quality infrastructure needed to support a first NDA or BLA approval.

Thank you for your consideration.

[Your Name]